Content |
BCI Pharma was founded in March 2013 by Dominic Surlero and Dr. Elizabeth Picu. With the support of molecular modeling, BCI has developed and created new molecules/compounds capable of inhibiting target kinases with very high selectivity, which improves the safety and tolerability profile of drugs in patients.
As of June 2024, the company is located at two sites: a team engaged medical in chemistry is located in Montpellier (), France and employees responsible for biotechnological development - in Liège (). Belgium
History
2024: Acquisition by Gedeon Richter
The company Gedeon Richter announced the purchase of Belgian BCI maker Pharma, a private biotechnology research company that develops in different areas of women's health. The deal is valued euro at 12 million, payable over several years, as certain results are achieved. This Zdrav.Expert became known on June 24, 2024.
BCI is working to find new kinase inhibitors from its own library of these small chemical molecules, as well as from its HTS (High Throughput Screening) derived database. Potential drug candidates are identified using current screening studies regarding clinically confirmed biological targets.
Шаблон:Quote 'author = said Peter Turek, Head of Women's Health at Gedeon Richter.
2017: Raising funding from Noshaq and other private Belgian investors
In September 2017, the company raised Series A funding from Noshaq and other private Belgian investors, moved its headquarters to Belgium and opened a biological laboratory in Liège.
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |